Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1/2 study of SOT109 in advanced colorectal cancer
2026-526235-19-00Phase 2Authorised
- Sponsor
- SOTIO Biotech
- Start
- Oct 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of SOT109 in colorectal cancer (CRC) (3 arms), sponsored by SOTIO Biotech. Primary endpoints: Maximum tolerated dose and recommended phase 2 dose, Safety and tolerability of two recommended doses and 1 more. Planned start Oct 2026; status: authorised.
02
Drugs
SOT109
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2026-526235-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526235-19-00.